Review
This article reviews the biology, clinicopathological characteristics, targeted therapies and mechanisms of resistance of advanced non-small-cell lung cancer harbouring RET fusions to provide treatment guidance for these patients.
Review
In this article, the authors focus on the management of patients with MET exon 14 skipping alterations by addressing the biology of the MET receptor and exon 14 skipping mutations, current treatment strategies, and sequential treatment options based on resistance mechanisms to MET inhibitors in patients with non-small-cell lung cancer.
